Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection

Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection

IntroductionTranscutaneous immunization (TCI) is a non-invasive vaccination method promoting strong cellular immune responses, crucial for the immunological rejection of cancer. Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic d...

Full description

Bibliographic Details
Main Authors: Ann-Kathrin Hartmann, Joschka Bartneck, Jonas Pielenhofer, Sophie Luise Meiser, Danielle Arnold-Schild, Matthias Klein, Michael Stassen, Hansjörg Schild, Sabine Muth, Hans Christian Probst, Peter Langguth, Stephan Grabbe, Markus P. Radsak
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
trancutaneous immunization
imiquimod (IMQ)
dithranol (anthralin)
cytotoxic T lymphocytes (CTL)
tumor rejection
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1238861/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1238861/full

Similar Items